Gilead’s Re-Rating: A Shift Toward Durable Growth and Margin Visibility
From Value Trap to Visibility Play, Gilead’s Market Perception Has Changed - But Execution Still Matters.
Over the past 6–9 months, Gilead Sciences has undergone a quiet but powerful re-rating. Once viewed as a defensive value stock with limited growth, the company is now increasingly seen as a high-quality biotech franchise with visible margin expansion, commercial durability, and late-stage pipeline catalysts.
Total return since mid-October 2024 is +32%, far ahead of biotech benchmarks and in line with strong upward revisions in consensus margin forecasts.
The shift is visible across blended forward (BF) valuation metrics: Gilead now trades at a 2% premium on EV/EBITDA and near parity on EV/EBIT, erasing a multi-year discount. Its BF P/E has risen to 13.6x - ~2 standard deviations above historical norm - underscoring improved sentiment around earnings quality and capital efficiency.
Multiple high-margin growth drivers are coming into focus: lenacapavir for HIV prevention (approved June 2025), renewed HIV revenue growth in 2026, and potential 2026 launches for anito-cel and expanded Trodelvy labels. At the same time, operating discipline has returned Gilead to margin leadership in large-cap biotech.
With long-term estimates now stabilizing and stock momentum pausing, investors may be waiting for the next leg. Execution on 2026 catalysts will determine whether this is a new baseline, or just the setup for another step higher.
Risks to Watch
Medicare headwinds: Part D reforms will weigh on HIV revenue in 2025 (~$900M impact).
Pipeline dependency: Execution risk remains for key launches (lenacapavir, anito-cel, Trodelvy).
ADC competition: Trodelvy faces increasing pressure in breast and lung cancer.
Regulatory uncertainty: Shifting FDA timelines, global access issues may affect launch cadence.
Valuation compression: With multiples near historical peaks, any growth stumble could trigger derating.
New York City, NY. Hartaj Singh, Fall 2024
Coming Up on The Biotech Capital Compass
July 2025 – Gene Tech Showdown: Editing, Therapy & the Road Ahead
This July, the teams at Biotech Blueprint and Biotech Capital Compass are launching a three-part primer unpacking the evolving worlds of gene editing and gene therapy, two closely linked but fundamentally distinct technologies. We’ll move beyond the science to explore why these platforms matter, where they’ve stumbled, and what investors need to watch as the next chapter unfolds.
Biotech Capital Compass: July Newsletter
Welcome to The Biotech Capital Compass! Your Guide to the Fast-Moving World of Biotech Investing.
If you’re an active investor, swing trader, or simply biotech-obsessed, you’ve come to the right place. The Biotech Capital Compass delivers sharp analysis, market-moving insights, and actionable strategies tailored for those who want to stay ahead in this dynamic sector. Whether you’re trading biotech stocks daily, holding long-term positions, or just fascinated by the next breakthrough therapy, this newsletter is built for you.
We’re Leveling Up—Join the Inner Circle!
Starting January 2025, The Biotech Capital Compass moved to a premium subscription model, following an incredible three-month free run in late 2024. If you’re serious about navigating the high-stakes biotech market, now is the time to get in—exclusive insights, deep-dive analysis, and smart trading strategies await.
Let’s Build This Together!
Subscribers, your feedback, comments, and ideas are what make this community thrive. Engage, ask, challenge, and share your insights—because the best biotech investors learn from each other. Let’s make this the go-to hub for those who want to decode the biotech landscape and capitalize on its biggest opportunities.
Ready to take your biotech investing to the next level? Let’s dive in!
Disclosures at end of note.
About the Author
Hartaj Singh brings over 30 years of experience in drug development, corporate strategy, hedge fund management, and biotech analysis. With a career spanning top investment banks, Hartaj has been a highly ranked analyst, known for providing astute guidance on biotech investments for over a decade. His deep sector knowledge, honed through years of navigating the biotech landscape, is now being put to use to help investors capitalize on biotech opportunities.